Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05783609 · ClinicalTrials.gov registry record · Phase 2
Epcoritamab and Rituximab for First-line Follicular Lymphoma
A Phase 2 study of Follicular Lymphoma and Low Grade Non-Hodgkin's Lymphoma, Adult, sponsored by Reid Merryman, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 5
- Study locations
NCT05783609: Recruiting Phase 2 study of Follicular Lymphoma and Low Grade Non-Hodgkin's Lymphoma, Adult, sponsored by Reid Merryman, MD.
NCT05783609 is a Phase 2 study of Follicular Lymphoma and Low Grade Non-Hodgkin's Lymphoma, Adult that is actively recruiting participants, run by Reid Merryman, MD. The registered enrollment target is 100 participants, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (25% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05783609, a Phase 2 study of Follicular Lymphoma and Low Grade Non-Hodgkin's Lymphoma, Adult, is actively recruiting participants, sponsored by Reid Merryman, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a type of monoclonal antibody therapy) * Epcoritamab (a T-cell bispecific antibody)
Primary Outcome
EOT CMR rate defined as the proportion of participants achieving CR per PET/CT Lugano 2014 criteria (protocol appendix B) at the EOT assessment: PET-CT, score 1, 2, or 3 with or without a residual mass on a 5-point scale (5PS) among all patients and separately in Cohorts A and B.
Conditions Studied
Interventions
- DRUG Epcoritamab
- DRUG Rituximab
Study Locations (5)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
New York
- University of Rochester Medical Center - Rochester
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2030-02 |
| Phase | Phase 2 |
What NCT05783609 shows while recruiting
NCT05783609 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (25% lower).
The record links to 2 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Epcoritamab is the first listed.
NCT05783609 lists 5 locations in 4 states (Massachusetts, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT05783609 about?
NCT05783609 is a clinical study titled "Epcoritamab and Rituximab for First-line Follicular Lymphoma". The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a...
What is the current status of trial NCT05783609?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-06-21. Estimated completion is 2030-02.
What conditions does trial NCT05783609 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult.
What interventions are being tested in trial NCT05783609?
The interventions under investigation include: Epcoritamab (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT05783609?
This trial is sponsored by Reid Merryman, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05783609 being conducted?
This trial has 5 study locations across Massachusetts, New York, Ohio, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05783609's enrollment target sits among peer trials
100 30th of 89 higher than 57 of 89 other Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI